Back

Dapagliflozin's influence on cardiac remodeling in chronic heart failure patients

11 May 2024 (13:00 - 13:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - pathophysiology and mechanisms 7 Ventricular Remodelling HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Ana Rita Ribeiro Teixeira

University Hospital Lisboa Central, Lisbon (Portugal)

4 More presentations in this session

Presentation thumbnail
Prognostic implications of adaptive and maladaptive right ventricular hypertrophy in patients with heart failure: a prospective observational cohort study
Doctor L. Dinc Asarcikli (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Predictors of early left ventricular reverse remodelling and prognosis in new-onset heart failure of non-ischemic origin
Doctor T. Hnat (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Cardiac reverse remodeling and SGLT2ii: insight from hemodynamic forces analysis
Doctor S. Prosperi (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Safety and tolerability of diuretics withdrawal in heart failure with reduced ejection fraction. The REDICAE trial
Mr J. Torres Zamudio (Cordoba, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - pathophysiology and mechanisms 7

The Event

Event poster

Heart Failure 2024

11 May 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients
thumbnail
Congress Presentation
Association between dapagliflozin, cardiac biomarkers, and cardiac remodeling in patients with diabetes mellitus and heart failure: a post-hoc analysis of a randomized study
thumbnail
Congress Presentation
DAPA MODA: Dapaglifozin and cardiac remodeling in chronic heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources